Szepetowski Sarah, Saultier Paul, Andre Nicolas, Pauly Vanessa, Dupuis L Lee, Sung Lillian, Revon-Rivière Gabriel
Pediatric Oncology, Hôpital de la Timone, Marseille, Provence-Alpes-Côte d'Azur, France
Pediatric Oncology, Hôpital de la Timone, Marseille, Provence-Alpes-Côte d'Azur, France.
BMJ Support Palliat Care. 2023 Oct;13(e1):e70-e73. doi: 10.1136/bmjspcare-2020-002753. Epub 2021 Jan 15.
Childhood and adolescent cancer can result in high burden of distressing symptoms, particularly in high-risk malignancies. The Symptom Screening in Pediatrics Tool (SSPedi) is a reliable and valid approach to measure bothersome symptoms in paediatric patients receiving cancer treatments. Objective was to describe the feasibility of using SSPedi administration among paediatric patients with high-risk malignancies.
We conducted a single-centre, cross-sectional study of patients aged 8-18 years with high-risk malignancies in a French paediatric oncology unit. Patients self-reported the degree of bothersome symptoms using SSPedi and difficulty with SSPedi completion. The total SSPedi Score ranging from 0 to 60 (where 60 is worst) and most common moderately bothersome symptoms (scored ≥2 on 0-4 Likert Scale) were described. Feasibility was defined as more than 75% of patients agreeing to participate and more than 90% completion of SSPedi questionnaire.
Out of 16 patients approached, 1 declined participation. Median age was 13 years (IQR 8-19). All were able to self-report SSPedi without difficulty. Patients experienced a median number of 6 (range 0-15) bothersome symptoms (score >0). The mean total SSPedi Score was 12 (SD=9.4). Most common moderately bothersome symptoms were pain (8/15), changes in hunger (8/15) and feeling tired (7/15).
Patient-reported symptom assessment among children and adolescents with high-risk malignancies is feasible using SSPedi. These patients experience a high burden of bothersome symptoms.
儿童和青少年癌症会导致令人痛苦的症状负担加重，尤其是在高危恶性肿瘤中。儿科症状筛查工具（SSPedi）是一种可靠且有效的方法，用于测量接受癌症治疗的儿科患者的困扰症状。目的是描述在高危恶性肿瘤儿科患者中使用SSPedi进行评估的可行性。
我们在一家法国儿科肿瘤病房对8至18岁的高危恶性肿瘤患者进行了单中心横断面研究。患者使用SSPedi自行报告困扰症状的程度以及完成SSPedi的困难程度。描述了SSPedi总分范围为0至60（60为最差）以及最常见的中度困扰症状（在0至4李克特量表上得分≥2）。可行性定义为超过75%的患者同意参与，且超过90%的患者完成SSPedi问卷。
在16名被邀请的患者中，1名拒绝参与。中位年龄为13岁（四分位间距8 - 19岁）。所有患者都能毫无困难地自行报告SSPedi。患者经历的困扰症状中位数为6种（范围0 - 15种）（得分>0）。SSPedi总平均分是12分（标准差 = 9.4）。最常见的中度困扰症状是疼痛（8/15）、饥饿变化（8/15）和感到疲倦（7/15）。
使用SSPedi对高危恶性肿瘤儿童和青少年进行患者报告的症状评估是可行的。这些患者经历着较高的困扰症状负担。
